{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:25:38Z","timestamp":1791887138751,"version":"4.3.4"},"reference-count":51,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81473065, 71704194"],"award-info":[{"award-number":["81473065, 71704194"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>We aimed to assess the cost-effectiveness of (1) treating acute hepatitis C virus (HCV) vs. deferring treatment until the chronic phase and (2) treating all chronic patients vs. only those with advanced fibrosis; among Chinese genotype 1b treatment-na\u00efve patients who injected drugs (PWID), using a combination Daclatasvir (DCV) plus Asunaprevir (ASV) regimen and a Peg-interferon (PegIFN)-based regimen, respectively. A decision-analytical model including the risk of HCV reinfection simulated lifetime costs and quality-adjusted life-years (QALYs) of three treatment timings, under the DCV+ASV and PegIFN regimen, respectively: Treating acute infection (\u201cTreat at acute\u201d), treating chronic patients of all fibrosis stages (\u201cTreat at F0 (no fibrosis)\u201d), treating only advanced-stage fibrosis patients (\u201cTreat at F3 (numerous septa without cirrhosis)\u201d). Incremental cost-effectiveness ratios (ICERs) were used to compare scenarios. \u201cTreat at acute\u201d compared with \u201cTreat at F0\u201d was cost-saving (cost: DCV+ASV regimen\u2014US$14,486.975 vs. US$16,224.250; PegIFN-based regimen\u2014US$19,734.794 vs. US$22,101.584) and more effective (QALY: DCV+ASV regimen\u201414.573 vs. 14.566; PegIFN-based regimen\u201414.148 vs. 14.116). Compared with \u201cTreat at F3\u201d; \u201cTreat at F0\u201d exhibited an ICER of US$3780.20\/QALY and US$15,145.98\/QALY under the DCV+ASV regimen and PegIFN-based regimen; respectively. Treatment of acute HCV infection was highly cost-effective and cost-saving compared with deferring treatment to the chronic stage; for both DCV+ASV and PegIFN-based regimens. Early treatment for chronic patients with DCV+ASV regimen was highly cost-effective.<\/jats:p>","DOI":"10.3390\/ijerph17030800","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T09:37:09Z","timestamp":1580204229000},"page":"800","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Economic Evaluation of Hepatitis C Treatment Extension to Acute Infection and Early-Stage Fibrosis Among Patients Who Inject Drugs in Developing Countries: A Case of China"],"prefix":"10.3390","volume":"17","author":[{"given":"Yin","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Medical Statistics, School of Public Health, Sun Yat-Sen University, Guangzhou 510080, China"},{"name":"Sun Yat-sen Center for Migrant Health Policy, Sun Yat-Sen University, Guangzhou 510080, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5833-5020","authenticated-orcid":false,"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, School of Public Health, Sun Yat-Sen University, Guangzhou 510080, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"China-Australia Joint Research Center for Infectious Diseases, School of Public Health, Xi\u2019an Jiaotong University Health Science Center, Xi\u2019an 710000, China"},{"name":"Melbourne Sexual Health Center, Alfred Health, Melbourne VIC 3053, Australia"},{"name":"Central Clinical School, Faculty of Medicine, Monash University, Melbourne, VIC 3800, Australia"},{"name":"Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, School of Public Health, Sun Yat-Sen University, Guangzhou 510080, China"},{"name":"Sun Yat-sen Center for Migrant Health Policy, Sun Yat-Sen University, Guangzhou 510080, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ling","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, School of Public Health, Sun Yat-Sen University, Guangzhou 510080, China"},{"name":"Sun Yat-sen Center for Migrant Health Policy, Sun Yat-Sen University, Guangzhou 510080, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,1,28]]},"reference":[{"key":"ref_1","unstructured":"(2019, April 21). Global Hepatitis Report. Available online: https:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/hep.23726","article-title":"The impact of hepatitis c virus infection on work absence, productivity, and healthcare benefit costs","volume":"52","author":"Su","year":"2010","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1080\/13696998.2019.1600523","article-title":"Comparative financing analysis and political economy of noncommunicable diseases","volume":"22","author":"Jakovljevic","year":"2019","journal-title":"J. Med. Econ."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study","volume":"3","author":"Fitzmaurice","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/hep.29611","article-title":"Should we treat acute hepatitis c? A decision and cost-effectiveness analysis","volume":"67","author":"Bethea","year":"2018","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","article-title":"Spontaneous viral clearance following acute hepatitis c infection: A systematic review of longitudinal studies","volume":"13","author":"Micallef","year":"2006","journal-title":"J. Viral Hepat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of hiv, hbv, and hcv in people who inject drugs: A multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/j.1440-1746.2010.06238.x","article-title":"Reinfection with hepatitis c virus following sustained virological response in injection drug users","volume":"25","author":"Grebely","year":"2010","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1360-0443.2010.03140.x","article-title":"Mortality among regular or dependent users of heroin and other opioids: A systematic review and meta-analysis of cohort studies","volume":"106","author":"Degenhardt","year":"2011","journal-title":"Addiction"},{"key":"ref_10","unstructured":"World Health Organization (2016). Global Health Sector Strategy on Viral Hepatitis, 2016\u20132021, World Health Organization."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Pradat, P., Virlogeux, V., and Trepo, E. (2018). Epidemiology and elimination of hcv-related liver disease. Viruses, 10.","DOI":"10.3390\/v10100545"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1097\/01.aids.0000304695.54884.4f","article-title":"Incidence of hiv, hepatitis c and hepatitis b viruses among injection drug users in southwestern china: A 3-year follow-up study","volume":"21","author":"Ruan","year":"2007","journal-title":"AIDS"},{"key":"ref_13","first-page":"296958","article-title":"Prevalence and seroincidence of hepatitis b and hepatitis c infection in high risk people who inject drugs in china and thailand","volume":"2014","author":"Jackson","year":"2014","journal-title":"Hepat. Res. Treat."},{"key":"ref_14","first-page":"906","article-title":"The guideline of prevention and treatment for hepatitis c: A 2015 update","volume":"23","author":"Wei","year":"2015","journal-title":"Chin. J. Hepatol."},{"key":"ref_15","unstructured":"(2019, April 21). China FDA Approves the Listing of Daclatasvir and Asunaprevir, Available online: http:\/\/www.nmpa.gov.cn\/WS04\/CL2168\/329397.html."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/MCG.0000000000000109","article-title":"Current challenges and the management of chronic hepatitis c in mainland china","volume":"48","author":"Duan","year":"2014","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_17","first-page":"797","article-title":"Current knowledge and future perspectives on acute hepatitis c infection","volume":"21","author":"Hullegie","year":"2015","journal-title":"Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Cipriano, L.E., and Goldhaber-Fiebert, J.D. (2018). Population health and cost-effectiveness implications of a \u201ctreat all\u201d recommendation for hcv: A review of the model-based evidence. MDM Policy Pract., 3.","DOI":"10.1177\/2381468318776634"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/jgh.13223","article-title":"Cost-effectiveness of treating chronic hepatitis c virus with direct-acting antivirals in people who inject drugs in australia","volume":"31","author":"Scott","year":"2016","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/jgh.12041","article-title":"Assessing the cost-effectiveness of treating chronic hepatitis c virus in people who inject drugs in australia","volume":"28","author":"Visconti","year":"2013","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1136\/gutjnl-2016-311504","article-title":"Treatment scale-up to achieve global hcv incidence and mortality elimination targets: A cost-effectiveness model","volume":"66","author":"Scott","year":"2017","journal-title":"Gut"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"van Santen, D.K., de Vos, A.S., Matser, A., Willemse, S.B., Lindenburg, K., Kretzschmar, M.E., Prins, M., and de Wit, G.A. (2016). Cost-effectiveness of hepatitis c treatment for people who inject drugs and the impact of the type of epidemic; extrapolating from amsterdam, the netherlands. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0163488"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jhep.2016.02.007","article-title":"Prioritization of hcv treatment in the direct-acting antiviral era: An economic evaluation","volume":"65","author":"Martin","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s10198-016-0844-8","article-title":"Hepatitis c disease transmission and treatment uptake: Impact on the cost-effectiveness of new direct-acting antiviral therapies","volume":"18","author":"Bennett","year":"2017","journal-title":"Eur. J. Health Econ. HEPAC Health Econ. Prev. Care"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/hep.28497","article-title":"Is increased hepatitis c virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in uk prisons? A prevention benefit analysis","volume":"63","author":"Martin","year":"2016","journal-title":"Hepatology"},{"key":"ref_26","first-page":"783","article-title":"Economic evaluation of the hepatitis c virus treatment extension to early-stage fibrosis patients: Evidence from the piter real-world cohort","volume":"21","author":"Ruggeri","year":"2018","journal-title":"Value Health J. Int. Soc. Pharm. Outcomes Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/cid\/ciu066","article-title":"Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis c virus\u2013infected patients in a country with limited resources: The case of egypt","volume":"58","author":"Obach","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1080\/03007995.2018.1546678","article-title":"Cost-effectiveness of novel regimens for chinese patients with chronic hepatitis c","volume":"35","author":"Wu","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamainternmed.2015.6011","article-title":"Cost-effectiveness of early treatment of hepatitis c virus genotype 1 by stage of liver fibrosis in a us treatment-naive population","volume":"176","author":"Chahal","year":"2016","journal-title":"JAMA Intern. Med"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.drugpo.2015.07.004","article-title":"Hepatitis c virus (hcv) disease progression in people who inject drugs (pwid): A systematic review and meta-analysis","volume":"26","author":"Smith","year":"2015","journal-title":"Int. J. Drug Policy"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis c and advanced hepatic fibrosis","volume":"308","author":"Veldt","year":"2012","journal-title":"JAMA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of hepatitis c virus infection and the development of hepatocellular carcinoma: A meta-analysis of observational studies","volume":"158","author":"Morgan","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.idc.2018.02.003","article-title":"Strategies to reduce hepatitis c virus reinfection in people who inject drugs","volume":"32","author":"Martinello","year":"2018","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/infdis\/jiv220","article-title":"Hepatitis c virus reinfection and spontaneous clearance of reinfection--the inc3 study","volume":"212","author":"Grebely","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_35","unstructured":"(2019, April 21). China Health Statistics Yearbook, Available online: http:\/\/www.stats.gov.cn\/tjsj\/ndsj\/2018\/indexeh.htm."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0140-6736(18)32277-3","article-title":"Scaling up prevention and treatment towards the elimination of hepatitis c: A global mathematical model","volume":"393","author":"Heffernan","year":"2019","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","article-title":"Morbidity and mortality in compensated cirrhosis type c: A retrospective follow-up study of 384 patients","volume":"112","author":"Fattovich","year":"1997","journal-title":"Gastroenterology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"84","DOI":"10.7326\/M15-0617","article-title":"Prevention of hepatitis c by screening and treatment in U.S. Prisons","volume":"164","author":"He","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/cid\/cis1007","article-title":"Determinants of hepatitis c virus treatment completion and efficacy in drug users assessed by meta-analysis","volume":"56","author":"Dimova","year":"2013","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jvh.12711","article-title":"Treatment with direct-acting antiviral agents of hepatitis c virus infection in injecting drug users: A prospective study","volume":"24","author":"Boglione","year":"2017","journal-title":"J. Viral Hepat."},{"key":"ref_41","first-page":"S513","article-title":"Efficacy and safety of sofosbuvir\/velpatasvir in people with chronic hepatitis c virus infection and recent injecting drug use: The simplify study","volume":"66","author":"Grebely","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_42","first-page":"e0195117","article-title":"Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis c genotype 1b treatment-naive patients in china","volume":"13","author":"Lu","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"ref_43","unstructured":"(2019, April 02). People\u2019s Republic of China 2018 National Economic and Social Development Statistical Bulletin, Available online: http:\/\/www.stats.gov.cn\/tjsj\/zxfb\/201902\/t20190228_1651265.html."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Chen, G.F., Wei, L., Chen, J., Duan, Z.P., Dou, X.G., Xie, Q., Zhang, W.H., Lu, L.G., Fan, J.G., and Cheng, J. (2016). Will sofosbuvir\/ledipasvir (harvoni) be cost-effective and affordable for chinese patients infected with hepatitis c virus? An economic analysis using real-world data. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0155934"},{"key":"ref_45","first-page":"592","article-title":"Cost-effectiveness of nucleoside analog therapy for hepatitis b in china: A markov analysis","volume":"13","author":"Wu","year":"2010","journal-title":"Value Health J. Int. Soc. Pharm. Outcomes Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"279","DOI":"10.7326\/0003-4819-156-4-201202210-00005","article-title":"New protease inhibitors for the treatment of chronic hepatitis c: A cost-effectiveness analysis","volume":"156","author":"Liu","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jama.290.2.228","article-title":"Cost-effectiveness of treatment for chronic hepatitis c infection in an evolving patient population","volume":"290","author":"Salomon","year":"2003","journal-title":"JAMA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1572-0241.2005.40976.x","article-title":"Estimation of utilities for chronic hepatitis c from sf-36 scores","volume":"100","author":"Thein","year":"2005","journal-title":"Am. J. Gastroenterol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"22146","DOI":"10.7448\/IAS.20.1.22146","article-title":"Elimination of hcv as a public health concern among people who inject drugs by 2030\u2014What will it take to get there?","volume":"20","author":"Grebely","year":"2017","journal-title":"J. Int. AIDS Soc."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugpo.2019.07.016","article-title":"Elimination of hepatitis c virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all","volume":"72","author":"Grebely","year":"2019","journal-title":"Int. J. Drug Policy"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Pedlar, A., and Sandhu, P.J. (2019). Promoting treatment for hepatitis c in people who inject drugs: A review of the barriers and opportunities. J. Am. Assoc. Nurse Pract.","DOI":"10.1097\/JXX.0000000000000269"}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/17\/3\/800\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:20:45Z","timestamp":1760361645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/17\/3\/800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,28]]},"references-count":51,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["ijerph17030800"],"URL":"https:\/\/doi.org\/10.3390\/ijerph17030800","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,28]]}}}